Recombinant Human Integrin alpha X beta 2 Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Integrin alpha X beta 2 Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support adhesion of J45.01 human acute lymphoblastic leukemia T lymphocytes. >50% of cells will adhere at 10 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Integrin alpha X beta 2 protein
  

  Human Integrin alpha X (Phe20-Pro1107) Accession # P20702	Acidic Tail	6-His tag
  Human Integrin beta 2 (Gln23-Asn700) Accession # AAA59490	Basic Tail
  N-terminus		C-terminus

• Accession #: P20702 (Integrin alpha X) & AAA59490 (Integrin beta 6)
• N-terminal Sequence: Phe20 ( alpha X) & Gln23: predicted, no results obtained ( beta 2)
• Protein/Peptide Type: Recombinant Proteins
• Gene: ITGAX
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 128.9 kDa ( alpha X) & 83.1 kDa ( beta 2).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 149 kDa & 103 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Integrin alpha X beta 2 Protein, CF

• Integrin alpha X beta 2

Background

Integrin alpha X beta 2, also called CD11c/CD18, p150/95 or complement receptor type 4 (CR4), is one of four beta 2 integrins. The non-covalent heterodimer of 150 kDa alpha X/CD11c and 95 kDa beta 2/CD18 integrin subunits is expressed on macrophages, dendritic cells and hairy cell leukemias, with lower amounts on other myeloid cells and activated B, NK and some cytotoxic T cells (1‑7). Like other integrins, alpha X beta 2 has multiple activation states (3). In the presence of divalent cations and "inside-out" signaling, alpha X beta 2 is fully active and extended. The alpha X vWFA or I-domain, which contains the adhesion sites, forms the N-terminal head region with the alpha X beta-propeller and the beta 2 vWFA domain (1, 8). In the inactive state, the heterodimer flexes in the center at the alpha X thigh and calf domains and beta 2 I-EGF domains, impeding access to adhesion sites (1). The 1088 aa human alpha X/CD11c ECD shares 70‑76% aa sequence identity with mouse, rat and canine alpha X while the 678 aa human beta 2/CD18 ECD shares 81‑83% aa sequence identity with mouse, rat, cow, dog, goat, sheep, and pig beta 2. Potential alpha X isoforms containing 719 and 725 aa (as compared to full-length 1163 aa alpha X) lack the vWFA domain and the N-terminus. Active alpha X beta 2 shares some adhesion partners with alpha M beta 2/CD11b/CD18, including complement opsonin fragment iC3b, ICAMs, vWF and fibrinogen, and is expressed on many of the same cells (4‑11). However, alpha M beta 2 activity is often constitutive, while alpha X beta 2 activity requires cell activation (4‑7). alpha X beta 2 also binds osteopontin, Thy-1, plasminogen, heparin, and proteins with abnormally exposed acidic residues (11‑16). The adhesion events are important for proliferation, degranulation, chemotactic migration, and phagocytosis of complement-opsonized particles (5, 6, 9, 11, 12, 16). Mutations of beta 2, especially in the vWFA domain, cause leukocyte adhesion deficiency (LAD-1) and susceptibility to bacterial infections (17).

1. Corbi, A.L. et al. (1987) EMBO J. 6:4023.
2. Kishimoto, T.K. et al. (1987) Cell 48:681.
3. Hynes, R.O. (2002) Cell 110:673.
4. Arnaout, M.A. (1990) Blood 75:1037.
5. Postigo, A.A. et al. (1991) J. Exp. Med. 174:1313.
6. Beyer, M. et al. (2005) Respir. Res. 6:70.
7. Nicolaou, F. et al. (2003) Blood 101:4033.
8. Vorup-Jensen, T. et al. (2003) Proc. Natl. Acad. Sci. USA 100:1873.
9. Bilsland, C.A.G. et al. (1994) J. Immunol. 152:4582.
10. Pendu, R. et al. (2006) Blood 108:3746.
11. Sadhu, C. et al. (2007) J. Leukoc. Biol. 81:1395.
12. Schack, L. et al. (2009) J. Immunol. 182:6943.
13. Choi, J. et al. (2005) Biochem. Biophys. Res. Commun. 331:557.
14. Gang, J. et al. (2007) Mol. Cells 24:240.
15. Vorup-Jensen, T. et al. (2007) J. Biol. Chem. 282:30869.
16. Vorup-Jensen, T. et al. (2004) Proc. Natl. Acad. Sci. USA 102:1614.
17. Kishimoto, T.K. et al. (1987) Cell 50:193.

Bioinformatics

• Gene Symbol: ITGAX
• Uniprot:
  • P20702 (Integrin alpha X) & AAA59490 (Integrin beta 6)()